Stored placental blood for unrelated bone marrow reconstitution

Rubinstein, Pablo; Re, Rosenfield; Adamson, JW; Ce, Stevens

doi:10.1182/blood.v81.7.1679.1679

Cited by 362 publications

(124 citation statements)

References 97 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…[31][32][33][34][35][36][37][38][39] Among these, cord blood may be an ideal source because of its accessibility, the lack of risk to the mother or infant and of ethical barriers, and the fact that it is a painless procedure to donors, promising sources for autologous cell therapy and lower risk of viral contamination. 17,40 In particular, we can utilize the established UCB bank to construct a UCB-MSC bank network system for future use as an 'off-the-shelf' therapy.…”

Section: Discussionmentioning

confidence: 99%

The immunomodulatory activity of human umbilical cord blood‐derived mesenchymal stem cells in vitro

et al. 2009

View full text Add to dashboard Cite

SummaryBone marrow-derived mesenchymal stem cells (BM-MSC) are currently being investigated in preclinical and clinical settings because of their selfrenewal and multipotent differentiative capacity or their immunosuppressive function. However, BM may be detrimental because of the highly invasive donation procedure and BM-MSC decline with age. Therefore, MSC derived from other sources have been considered as an alternative. However, there is only limited knowledge on their immunomodulatory properties. Human umbilical cord blood (UCB) cells are good substitutes for BM-MSC because of the immaturity of newborn cells. In this study, we successfully isolated MSC from UCB. The morphological phenotypes, cell cycle status, surface markers and differentiation potential of these clonally expanded cells are consistent with BM-MSC. Furthermore, UCB-MSC expanded in vitro retain low immunogenicity and an immunomodulatory effect. Flow cytometry analysis showed that UCB-MSC did not express CD40, CD40 ligand, CD80, CD86 and major histocompatibility complex class II molecules. We have demonstrated that UCB-MSC are incapable of inducing allogeneic peripheral blood mononuclear cell (PBMC) proliferation and have a dose-dependent inhibition of PBMC immune responses in mixed lymphocyte reactions (MLR) and phytohaemagglutinin activation assays, even after interferon-c treatment. Additionally, we have found that UCB-MSC can suppress the function of mature dendritic cells. Using transwell systems, we have demonstrated an inhibition mechanism that depends on both cell contact and soluble factors. Based on the findings we conclude that banked UCB could serve as a potential alternative source of MSC for allogeneic application in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

The immunomodulatory activity of human umbilical cord blood‐derived mesenchymal stem cells in vitro

et al. 2009

View full text Add to dashboard Cite

show abstract

“…This "proof of principal" generated extreme interest in the possibility of collecting and cryopreserving P/CB stem cell preparations for transplantation into recipients who otherwise could not find a suitable human leukocyte antigen (HLA)matched unrelated donor. 5 With this as background, the New York Blood Center (NYBC) established a public P/CB collection, processing, cryopreservation and distribution effort to support patients in need of transplants who had no HLA-matched marrow donor (related or otherwise) available. 5 The program was initiated in 1992 with funding from the National Heart, Lung and Blood Institute of the National Institutes of Health.…”

Section: Introductionmentioning

confidence: 99%

The Placental/Umbilical Cord Blood Program of the New York Blood Center A Progress Report

Rubinstein

Adamson

Stevens

1999

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

The transplantation of placental/umbilical cord blood (P/CB) has been used successfully to reconstitute bone marrow function in both related and unrelated recipients. We report here the experience of the New York Blood Center P/CB Program. Since its inception in 1992, over 400 unrelated transplants were supported between July 1993 and September 1997. Overall, event-free survival for all diagnoses and ages approached 0.45. Success and rapidity of engraftment correlated most strongly with the degree of human leukocyte antigen (HLA) disparity and cell dose/kg body weight recipient. Acute graft-versus-host disease (GVHD) was common in all patients but, surprisingly, did not differ between those patients who received grafts having one or more antigen mismatches. Chronic GVHD was uncommon and only rarely contributed to death. These results demonstrate the feasibility of large-scale P/CB banking for the provision of cryopreserved stem cell preparations for unrelated transplants. The degree of the program's success argues strongly for additional P/CB banks in order to increase the likelihood of finding a suitable stem cell preparation for patients for whom related matched donors do not exist.

show abstract

“…To address this need, Rubinbe collected and stored by expectant parents for potenstein and colleagues at the New York Blood Center tial use by the newborn infant (e.g., autologous transcreated the first public umbilical cord blood bank, plantation) or a family member in need of a stem cell specifically designed to test the safety and efficacy transplant procedure. Although these autologous and of collecting, testing, cryopreserving, and dispersing directed-allogeneic collections have typically been umbilical cord blood collected from unrelated donors performed by private (for-profit) cord blood banks, to transplant centers (6,11,12 These reports provide critically important and en-Public cord blood banks generally collect umbilical cord blood from a limited number of collection sites couraging results for the initial transplant experience with dedicated, trained personnel performing the col-Collection from Preterm Infants lections. To ensure that the collection of cord blood does not interfere with the normal birth process, these Although most public cord blood banks will collect umbilical cord blood from term, appropriate-for-gesta-banks usually collect it in an area separate from the delivery suite after delivery of the placenta.…”

Section: Umbilical Cord Blood Collection Banking and Transplantatiomentioning

confidence: 99%

Umbilical Cord Blood Collection, Banking, and Transplantation: Current Status and Issues Relevant to Perinatal Caregivers

Smith

Thomson

2000

Birth

View full text Add to dashboard Cite

As a result of recent media coverage of cord blood transplantation, expectant parents increasingly ask perinatal caregivers about the possibility of collecting and saving their newborn child's umbilical cord blood. Umbilical cord blood has been used as a source of hematopoeitic stem cells for the treatment of human disease since 1988. As a result of these initial successes, cord blood collection, banking, and transplantation has become increasingly used worldwide, giving rise to several controversies. We have reviewed the current status of the indications for cord blood collection, the methods of collection, and safety issues related to the cyropreservation of cord blood units. In addition, the clinical success of cord blood transplants from related and unrelated donors is detailed. We have examined the major issues concerning cord blood transplantation as it exists in the year 2000 to provide insight into this exciting area of clinical investigation.

show abstract

Stored placental blood for unrelated bone marrow reconstitution

Cited by 362 publications

References 97 publications

The immunomodulatory activity of human umbilical cord blood‐derived mesenchymal stem cells in vitro

The immunomodulatory activity of human umbilical cord blood‐derived mesenchymal stem cells in vitro

The Placental/Umbilical Cord Blood Program of the New York Blood Center A Progress Report

Umbilical Cord Blood Collection, Banking, and Transplantation: Current Status and Issues Relevant to Perinatal Caregivers

Contact Info

Product

Resources

About